Crizotinib is an ALK/ROS1/MET inhibitor for ALKor ROS1-positive non-small cell lung cancer (NSCLC). It falls under kinase inhibitors. These inhibitors stop lots of different kinases at the same time.
They offer two strengths. You’ve got 200 mg and then the 250 mg stuff. You’re supposed to go for the 250 mg stuff twice each day, by mouth.
It doesn’t matter if you’ve eaten or not. They come in bottles, with about 60 caps inside each one.
Reviews
There are no reviews yet.